These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19707464)

  • 1. Abatacept in difficult-to-treat juvenile idiopathic arthritis.
    Kuemmerle-Deschner JB; Benseler S
    Biologics; 2008 Dec; 2(4):865-74. PubMed ID: 19707464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
    Hara R; Umebayashi H; Takei S; Okamoto N; Iwata N; Yamasaki Y; Nakagishi Y; Kizawa T; Kobayashi I; Imagawa T; Kinjo N; Amano N; Takahashi Y; Mori M; Itoh Y; Yokota S
    Pediatr Rheumatol Online J; 2019 Apr; 17(1):17. PubMed ID: 31039807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable Efficacy of Abatacept Used as First-line or Second-line Biological Agent for Severe Juvenile Idiopathic Arthritis-related Uveitis.
    Birolo C; Zannin ME; Arsenyeva S; Cimaz R; Miserocchi E; Dubko M; Deslandre CJ; Falcini F; Alessio M; La Torre F; Denisova E; Martini G; Nikishina I; Zulian F
    J Rheumatol; 2016 Nov; 43(11):2068-2073. PubMed ID: 27633826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs.
    Ungar WJ; Costa V; Hancock-Howard R; Feldman BM; Laxer RM
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):111-9. PubMed ID: 20740607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
    Davies R; Gaynor D; Hyrich KL; Pain CE
    Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.
    Ruperto N; Lovell DJ; Quartier P; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhães C; Sztajnbok F; Goldenstein-Schainberg C; Scheinberg M; Penades IC; Fischbach M; Orozco J; Hashkes PJ; Hom C; Jung L; Lepore L; Oliveira S; Wallace CA; Sigal LH; Block AJ; Covucci A; Martini A; Giannini EH; ;
    Lancet; 2008 Aug; 372(9636):383-91. PubMed ID: 18632147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Children with Juvenile Idiopathic Arthritis.
    Viswanathan V; Murray KJ
    Indian J Pediatr; 2016 Jan; 83(1):63-70. PubMed ID: 26639461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab for treating juvenile idiopathic arthritis.
    Turnier JL; Brunner HI
    Expert Opin Biol Ther; 2016; 16(4):559-66. PubMed ID: 26848760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study.
    Brunner HI; Tzaribachev N; Vega-Cornejo G; Louw I; Berman A; Calvo Penadés I; Antón J; Ávila-Zapata F; Cuttica R; Horneff G; Foeldvari I; Keltsev V; Kingsbury DJ; Viola DO; Joos R; Lauwerys B; Paz Gastañaga ME; Rama ME; Wouters C; Bohnsack J; Breedt J; Fischbach M; Lutz T; Minden K; Miraval T; Ally MMTM; Rubio-Pérez N; Solau Gervais E; van Zyl R; Li X; Nys M; Wong R; Banerjee S; Lovell DJ; Martini A; Ruperto N;
    Arthritis Rheumatol; 2018 Jul; 70(7):1144-1154. PubMed ID: 29481737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.
    Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ
    Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reintroduction of immunosuppressive medications in pediatric rheumatology patients with histoplasmosis: a case series.
    Brown RA; Barbar-Smiley F; Yildirim-Toruner C; Ardura MI; Ardoin SP; Akoghlanian S
    Pediatr Rheumatol Online J; 2021 Jun; 19(1):84. PubMed ID: 34098976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on biologicals for treatment of juvenile idiopathic arthritis.
    Horneff G
    Expert Opin Biol Ther; 2013 Mar; 13(3):361-76. PubMed ID: 23289865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis.
    Brunner HI; Wong R; Nys M; Kou TD; Dominique A; Martini A; Lovell DJ; Ruperto N;
    Paediatr Drugs; 2020 Dec; 22(6):653-672. PubMed ID: 33029724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis.
    Thomas J; Kuthyar S; Shantha JG; Angeles-Han ST; Yeh S
    Ann Eye Sci; 2021 Jun; 6():. PubMed ID: 34131629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)].
    Bukovac LT; Vidović M; Lamot L; Perica M; Harjacek M;
    Reumatizam; 2013; 60(1):57-66. PubMed ID: 24003687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic therapies for juvenile idiopathic arthritis-associated uveitis.
    Dini G; Dell'Isola GB; Beccasio A; Di Cara G; Verrotti A; Cagini C
    Front Ophthalmol (Lausanne); 2022; 2():954901. PubMed ID: 38983531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry.
    Lovell DJ; Tzaribachev N; Henrickson M; Simonini G; Griffin TA; Alexeeva E; Bohnsack JF; Zeft A; Horneff G; Vehe RK; Staņēviča V; Tarvin S; Trachana M; Del Río AQ; Huber AM; Kietz D; Orbán I; Dare J; Foeldvari I; Quartier P; Dominique A; Simon TA; Martini A; Brunner HI; Ruperto N;
    Rheumatology (Oxford); 2024 Sep; 63(SI2):SI195-SI206. PubMed ID: 38243722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
    Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
    Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.